Retrospective analysis of patients with hepatocellular carcinoma complicated with human immunodeficiency virus infection after hepatectomy

Table 2 Clinical data for patients in the nonsurgical group

Indicator	n = 29
Age (years)	60.38 ± 7.49
Gender (Male:female)	23:6
HIV initial diagnosis, n (%)	17 (58.6)
HIV-RNA positive, n (%)	20 (69.0)
MSM, n (%)	14 (48.3)
Received HART after HIV diagnosis	12 (41.4)
HBV, n (%)	21 (72.4)
HCV, n (%)	4 (13.8)
Chronic alcohol consumption, n (%)	11 (37.9)
CD4+ cell count < 200 (cell/μL)	18 (62.1)
Child-Pugh score (A:B)	14:15
BCLC staging (0-B:C-D)	12:17
CNLC Staging (Ia-IIa:IIb-IIIa)	14:15
AFP (ng/mL)	179.01 (1.64-848.74)
ALT (U/L)	23.66 ± 17.51
AST (U/L)	29.00 ± 20.56
TBIL	14.98 ± 6.82
DBIL	4.29 ± 2.49
IBIL	10.96 ± 4.86
Prothrombin time (second)	13.82 ± 2.11
Albumin	34.37 ± 5.43
Hemoglobin	129.55 ± 14.46
White blood cell count (/L)	5.41 ± 3.95
Platelet count (/L)	168.14 ± 73.22
Tumor maximum diameter (mm)	37 (9-115)
Tumor solitary:multiple	13:16
Hepatic encephalopathy (n)	0
Ascites, n (%)	7 (24.1)
PS score (0-1:2-3, cases)	19:10

HART: Highly active antiretroviral therapy; HIV: Human immunodeficiency virus; MSM: Men who have sex with men; HBV: Hepatitis B Virus; HCV: Hepatitis C Virus; AFP: Alpha-fetoprotein; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; TBIL: Total bilirubin; DBIL: Direct bilirubin; IBIL: Indirect bilirubin; MVI: Microvascular invasion.